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Background: Dyslipidemia and abnormal phospholipid metabolism are frequent in uremic patients and increase
their risk of cardiovascular disease (CVD): ω-3 polyunsaturated fatty acids (PUFAs) may reduce this risk in the general
population. In this study we compared the plasma and erythrocyte cell membrane composition of PUFAs in a
group of Caucasian hemodialysis (HD) patients and in a control group of healthy subjects and evaluated the
erythrocyte/cell membrane fatty acid ratio as a marker of the dietary intake of phospholipids. The relationship
between ω-3 and ω-6 fatty acids and the possible differences in PUFAs concentrations were also investigated.
Methods and results: After obtaining a fully informed consent, a total of ninety-nine HD patients and 160 non
uremic control subjects from “Tor Vergata” University Hospital were enrolled into the study. None of them took
antioxidant drugs or dietary supplements for at least 90 days prior to the observation. Blood samples were analysed
by gas-chromatographic coupled to a mass spectrometric detector.
The daily intake of total calories, proteins, lipids and carbohydrates is significantly lower in HD patients than in
controls (p < 0.001). Most plasma and erythrocyte PUFA were also reduced significantly in HD patients (p < 0.001).
Conclusions: Our results suggest that many classes of PUFAs are lacking in HD patients, due to the removal of
nutrients during the dialysis and to persistent malnutrition. A dietary treatment addressed to increase plasma ω-3
PUFAs and to optimize ω-6/ω-3 ratio may exert a protective action and reduce the risk of CVD in HD patient.
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Cardiovascular (CV) morbidity and mortality are in-
creased in hemodialysis (HD) patients compared to the
general population regardless of gender, age, race and the
presence of diabetes mellitus. In particular, CV mortality
observed in uremic patients aged 25 to 35 years equals
that observed in the general population aged over 85 [1].
The evaluation of these traditional risk factors does not
explain the phenomenon completely; it is therefore neces-
sary to examine other factors associated with chronic renal
failure such as proteinuria, chronic inflammation, oxida-
tive stress, electrolyte disturbances and malnutrition in
particular. However, previous investigations on plasma* Correspondence: didaniele@med.uniroma2.it
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unless otherwise stated.and erythrocyte concentration of fatty acids in end-stage
renal disease (ESRD) patients yielded to contradictory re-
sults [2-5].
As kidney function declines, an altered lipid profile is ob-
served in renal patients: total cholesterol, LDL-cholesterol
and triglycerides are significantly increased, while HDL-
cholesterol is significantly reduced. Low HDL-cholesterol is
always associated with hypertriglyceridemia and it is strictly
linked to the changes in triglyceride metabolism [6]. Ac-
cordingly, Chronic Kidney Disease (CKD) patients show
lipid and lipoprotein metabolism disturbances and changes
in the metabolism of fatty acids may also develop [7].
Currently, there are no studies designed to investigate
the composition of plasma and erythrocyte PUFAs in HD
patients in Italy. Aim of the present study was thus to
compare plasma and erythrocyte PUFA composition in atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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healthy subjects, in order to investigate the presence of a
further cardiovascular risk factor in an established high-risk
population. The average diet followed during the last twelve
months prior to the study was considered. We measured
erythrocyte fatty acids as a marker of cell membrane fatty
acids as well as of the phospholipid dietary intake.
Methods
Study population
The study protocol complied with the Declaration of
Helsinki and was appointed by the Ethics Committee of the
University Hospital of “Tor Vergata”. Both men and women
over the age of 18 years were eligible for the study. A writ-
ten fully informed consent was provided by all participants
before enrollment into the study. The study population
consisted of a total of 99 ESRD patients on maintenance
HD relating to the Department of “Nephrology and Hyper-
tension” of the University Hospital of “Tor Vergata” (“study
group”) and 160 healthy volunteers enrolled at the Depart-
ment of Occupational Medicine of “Tor Vergata” University
(“control group”). ESRD patients received standard bicar-
bonate hemodialysis with 1.5-2sqm low flux polysulfone
membranes for four hours, three times weekly since at least
three months. Healthy controls had no history of renal dis-
ease, diabetes, hypertension, dyslipidemia, liver disease or
cancer. They didn’t take any drug or medication.
Anthropometry and traditional CV risk profile
The Body Mass Index (BMI) was calculated at enrollment
as body weight divided by height squared (kg/m2). The
post-dialysis body weight (“dry weight”) was considered in
HD patients.
Systolic and diastolic blood pressures were registered
before dialysis in ESRD patients and at enrollment in
healthy controls.
Serum lipid profile components and glucose were deter-
mined by The Dimension VISTA 1500 equipment (SIE-
MENS healthcare Diagnostic, Germany) in all the study
population.
Dietary pattern
We used a questionnaire validated by INRAN (National
Research Institute for Food and Nutrition) [8] to investi-
gate the dietary habits of HD patients and control sub-
jects. Frequency of meals and amount of food consumed
by the subjects enrolled into the study were evaluated
during the twelve months preceding the measurement of
plasma and erythrocyte membrane PUFAs. A question-
naire that assessed the eating habits of all subjects en-
rolled was given to each one to ascertain the frequency
of consumption of certain foods for a given period of
time (week, month, year). A total of 790 different foods
with as many as 67 different nutrients were investigated,not all available for all foods. Shortcomings still exist re-
garding in particular the vitamins and trace elements.
The INRAN_QUEST_SCAI_2005 software developed in
ACCESS 2003 was employed for the analysis of the
questionnaires.
Plasma and erythrocyte lipid measurement
Erythrocyte membrane polyunsaturated fatty acid (PUFA)
methyl esters were extracted using a modified version of
previously reported methods [9-11] and analyzed by a gas-
chromatography equipment (GC, model 6890 N, Agilent
Technologies Italia Spa), coupled to a mass spectrometric
detector (MSD, model Agilent 5973 inert, Agilent Tech-
nologies Italia Spa).
Statistical analysis
Quantitative variables were expressed as means ± stand-
ard deviation. Categorical variables were presented as
numbers and percentages.
The presence of skewed data was evaluated using visual
inspection of Q-Q plots, stem and leaf plots, or box plots
and verified using the Shapiro-Wilk test for normal distribu-
tion. Unpaired t test was employed to compare the data be-
tween uremic patients and healthy subjects (controls); non
parameter variables were analyzed by Mann–Whitney test.
The significance of the difference between percentages
in groups was evaluated using the chi-square test.
The analysis of covariance was used to correct the dif-
ferences between the variables of interest for age, gender,
smoke and BMI. P-value <0.05 was considered statisti-
cally significant.
Analysis was performed with the SPSS 15.0 software
for Windows platforms, (SPSS, Inc., Chicago, IL).
Results
The epidemiological and anthropometric features of the
whole study population are summarized in Tables 1 and 2.
ESRD patients showed a lower total calories daily intake,
lower vegetable/animal lipid and protein content, lower
carbohydrate, fibers and retinol intake compared to
healthy controls (p < 0.0001). Fish intake was not signifi-
cantly different between the two groups (Table 3).
Plasma triglycerides, total cholesterol and LDL-cholesterol
were significantly higher (p < 0.0001, p < 0.05 and p < 0.05
respectively) while HDL-cholesterol was significantly lower
(p < 0.05) in uremic patients compared to control subjects.
Plasma composition in phospholipids and fatty acids in
HD patients (n = 99) and in healthy subjects (n = 160) is
shown in Table 4. Several statistically significant differ-
ences are observed in HD patients compared to healthy
subjects: plasma linoleic acid, dihomo- γ-linolenic acid ,
arachidonic acid and eicosapentaenoic acid are signifi-
cantly reduced in HD patients (p < 0.0001, p < 0.0001,
p < 0.0001 and p = 0.0081 respectively), while plasma γ-
Table 1 Anthropometric and clinical characteristics correlations between HD patients and healthy subjects (controls)
HD (n = 99) Controls (n = 160) p
Age (years) 69.3 ± 14.7 61.3 ± 7.1 <0.01
Gender (male %) 59.6 100 <0.01
BMI (kg/m2) 23.0 ± 1.2 22.1 ± 1.5 <0.01
Fasting glucose (mg/dl) 125.2 ± 51.6 91.3 ± 19.3 <0.01
Blood urea nitrogen (before dialysis) 127.6 ± 43.4 - n.a
Blood urea nitrogen (after dialysis) 39.8 ± 16.7 - n.a.
Creatinin (mg/dl) 8.0 ± 2.8 0.9 ± 0.4 <0.01
Dialytic vintage (months) 65.8 ± 64.8 - n.a
Smoking (%) 15.1 5.0 <0.01
Diabetes mellitus (%) 23.2 0 n.a.
Hypertension (%) 79.8 0 n.a.
C-reactive protein 2.4 ± 5.5 1.4 ± 2.7 <0.01
P-Value <0.05 is statistically significant.
HD: hemodialysis. BMI: body mass index n.a.: not applicable.
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tients (p < 0.0001). Finally, we did not observe between
the two groups significant differences between plasma
α-linolenic acid (p = 0.4460) and docosahexaenoic acid
(p = 0.4389). In addition, the ω-6/ω-3 PUFAs ratios were
calculated (ARA/EPA and ARA/DHA). We did not ob-
serve any significant difference in the ARA/DHA ratios
between the two groups (Table 4) but we observed sta-
tistically significant difference in ARA/EPA ratios be-
tween HD patients and healthy subjects (Table 4).This
last difference was not confirmed after adjustment for
covariates possibly affecting plasma PUFAs concentra-
tion in HD patients and healthy controls, such as age,
gender, cigarette smoking and BMI (Table 4).
Instead, for all other variables the statistical significances
detected were confirmed even after adjustment for covari-
ates previously described (Table 4).
Erythrocyte membrane composition in phospholipids
and fatty acids in HD patients (n = 99) and in healthy sub-
jects (n = 160) is shown in Table 5 as well. In particular,Table 2 Epidemiologic data of the study population
HD Controls
Primary causes of end-stage renal disease
Nephroangiosclerosis (%) 39.4 -
Chronic glomerulonephritis (%) 31.3 -
ADPKD (%) 17.2 -
Chronic pyelonephritis (%) 12.1 -
Drug therapy
Statins (%) 0 0
Antihypertensive drugs (%) 79.8 0
Anticoagulants (%) 65.6 0
HD: hemodialysis, ADPKD: Autosomal dominant polycystic kidney disease.we observed that plasma linoleic acid (p < 0.0001),
dihomo-γ-linolenic acid (p <0.0001), arachidonic acid (p <
0.0001) and α-linolenic acid (p < 0.0001) was significantly
reduced in HD patients compared to controls, while
plasma γ-linolenic acid (p < 0.0001) was significantly in-
creased. On the other hand, plasma eicosapentaenoic acid
(p = 0.0907) and docosahexaenoic acid (p = 0.0651) was
not statistically different between the two groups, whereas
the erythrocyte PUFAs ratios, ARA/EPA (p < 0.0001) and
ARA/DHA (p < 0.0001), were significantly decreased in
HD patients compared to healthy subjects (Table 5). Fi-
nally, we observed that the two groups had a comparable
ω-3 index (EPA +DHA). Multivariate analysis, matched
for age, gender, cigarette smoking and BMI, confirmed the
differences observed.Discussion
Chronic Kidney Disease (CKD) patients show lipid and
lipoprotein metabolism disturbances [7]. Phosphati-
dylinositol and phosphatidic acid are not present in the
erythrocyte membranes of CKD patients. Rheological
properties of erythrocytes, such as osmotic resistance,
deformability and mechanical fragility change in these
patients. Many authors associate these disturbances
with the lipid composition of the erythrocyte membrane
[12]. During hemodialysis total cholesterol content and
the cholesterol/phospholipids ratio increase in the cyto-
plasmic membrane. These are the main factors res-
ponsible for the alterations of membrane fluidity that
potentially impact on erythrocyte deformability and
osmotic resistance [13].
An abnormal phospholipid metabolism was suggested
to play an important role in the progression of athero-
sclerosis in hemodialysis patients [14].
Table 3 Comparison of the daily dietary consumption in HD patients versus the control group
Daily dietary composition HD (n = 99) Controls (n = 160) P-value
Kcal (kcal) 1204.0 ± 275.8 1902.0 ± 280.8 <0.001
Vegetable protein (g) 26.8 ± 6.5 62.3 ± 7.5 <0.001
Animal protein (g) 34.5 ± 8.85 77.3 ± 9.95 <0.001
Vegetable lipids (g) 18.9 ± 4.4 57.8 ± 5.3 <0.001
Animal lipids (g) 23.8 ± 8.3 31.4 ± 7.6 <0.05
Fish (daily servings) 0.7 ± 0.32 0.9 ± 0.41 ns
Carbohidrates (g) 164.8 ± 36.9 304.8 ± 48.3 <0.001
Fiber (g) 0.75 ± 0.35 28.9 ± 0.56 <0.001
Retinol (ug) 118.9 ± 41.3 499.8 ± 43.4 <0.001
Niacin (mg) 12.8 ± 3.8 14.7 ± 4.8 ns
Vitamin E (mg) 9.9 ± 4.6 8.8 ± 2.9 ns
Cholesterol (mg) 264.4 ± 88.9 255.3 ± 93.4 ns
P-Value <0.05 is statistically significant.
HD: hemodialysis. Ns = non significant.
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association between CVD and dietary intake or plasma
concentrations of omega-3 PUFAs, primarily eicosapenta-
enoic acid (EPA) and docosahexaenoic acid (DHA), sug-
gesting that supplementation of ω-3 fatty acid might exert
protective effects on CVD [15-19]. The protective action
of ω-3 fatty acids upon the CV system is mediated by their
ability to suppress inflammation and to inhibit platelet
activation/adhesion, as well as by a direct effect on the
myocardium [20]. This latter effect is related to their cap-
acity to prolong the refractory state of cardiomyocytes via
an interaction with fast-acting sodium channels and the L-
type calcium channels. These actions are mediated by EPA
and DHA in cardiomyocyte membranes. A comparativeTable 4 Plasma phospholipids
Fatty acids (μmol/L) HD (n = 99)
Polyunsatured ω-6:
Linoleic acid (18:2) 1387.30 ± 340.15
Γ-Linolenic acid (18:3) 29.20 ± 14.83
Dihomo-γ-linolenic acid (20:3) 110.68 ± 38.99
Arachidonic acid (20:4) 437 ± 111.45
Polyunsatured ω-3:
Α-Linolenic acid (18:3) 18.35 ± 14.57
Eicosapentaenoic acid (20:5) 28.95 ± 37.49
Docosahexaenoic acid (22:6) 142.10 ± 67.86
ω-6/ω-3:
ARA/EPA 28.54 ± 20
ARA/DHA 4.06 ± 1.53
Ω-3 Index:
EPA + DHA 179.46 ± 110.92
P <0.05 is statistically significant, p* = differences between the two groups controlle
HD: hemodialysis. ARA: arachidonic acid. EPA: eicosapentaenoic acid. DHA=: docosastudy revealed a strong correlation between n-3 fatty acids
concentration in myocardium and in erythrocytes [21].
ESRD patients on maintenance HD are at risk for inad-
equate ω-3 intake because they may find foodstuffs less
palatable as a result of alterations in taste; moreover, renal
dietary recommendations do not encourage fish consump-
tion due to adverse hyperphosphatemia [22]. Therefore,
malnutrition is a frequent occurrence in HD patients
and may be caused by either inadequate food intake and
enhanced intradialytic loss of nutrients, or by hypercatab-
olism due to ESRD comorbidities or associated to dialysis
treatment [23].
Phospholipids play an essential role in cell membrane
structure and function. The length and degree ofControls (n = 160) p-value p*
1757.48 ± 289.93 <0.0001 <0.0001
14.79 ± 9.72 <0.0001 <0.0001
175.37 ± 65.68 <0.0001 <0.0001
504.52 ± 133 <0.0001 <0.0001
15.58 ± 9.62 0.4460 0.069
39.95 ± 54.82 0.0081 0.016
150.51 ± 78.13 0.4389 0.508
25 ± 17 0.0081 0.136
3.48 ± 1.48 0.068 0.106
182.11 ± 111.96 0.832 0.294
d for gender, age, BMI and smoke.
hexaenoic acid.
Table 5 Erythrocyte phospholipids
Fatty acids (μmol/L) HD (n = 99) Controls (n = 160) p-value p*
Polyunsatured ω-6:
Linoleic acid (18:2) 398.83 ± 119.03 684.04 ± 133.4 <0.0001 <0.0001
Γ- Linolenic acid (18:3) 1.73 ± 1.09 0.99 ± 0.42 <0.0001 <0.0001
Dihomo-γ-linolenic acid (20:3) 45.56 ± 21.14 86.94 ± 35.57 <0.0001 <0.0001
Arachidonic acid (20:4) 455.66 ± 236.66 560.37 ± 97.66 <0.0001 0.018
Polyunsatured ω-3:
Α-Linolenic acid (18:3) 0.71 ± 0.4 1.02 ± 0.3 <0.0001 <0.0001
Eicosapentaenoic acid (20:5) 9.74 ± 11.8 7.43 ± 11.47 0.0907 0.334
Docosahexaenoic acid (22:6) 132.44 ± 81.39 136.48 ± 42.51 0.0651 0.001
ω -6/ω-3:
ARA/EPA 83.92 ± 51.43 133.16 ± 74.62 <0.0001 0.002
ARA/DHA 4.13 ± 4.4 4.48 ± 1.62 <0.0001 0.002
Ω-3 Index:
EPA + DHA 192.19 ± 139.73 143.95 ± 50.10 0.0542 0.876
P <0.05 is statistically significant p* = differences between the two groups controlled for gender, age, BMI and smoke.
HD: hemodialysis. ARA: arachidonic acid. EPA: eicosapentaenoic acid. DHA=: docosahexaenoic acid.
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minants of cell membrane fluidity, transport systems, activ-
ity of membrane-bound enzymes and susceptibility to lipid
peroxidation [24]. The serum fatty acid lipid profile (espe-
cially phospholipids) reflects the fatty acid composition of
cell membranes [25]. In our study, HD patients had re-
duced plasma EPA, ARA, LA and Dihomo-γ-linolenic acid
(DGLA), associated with high plasma triglycerids.
Christensen and Coworkers demonstrated a possible anti-
arrhythmic effect of ω-3 PUFAs, as they found a positive
correlation between Heart Rate Variability (HRV) and the
composition in cell membrane of ω-3 PUFAs in CKD pa-
tients [26]. Further intervention studies based on the admin-
istration of ω-3 confirmed the ω-3 PUFAs cardio-protective
role [27,28] and showed that the composition of erythrocyte
EPA and DHA reflects that of the myocardium and is influ-
enced by diet [29]. We thus investigated erythrocyte mem-
brane EPA and DHA as its “ω 3-index” (EPA+DHA)
correlates to human myocardiocyte membrane ω 3-index.
We found a significant reduction of erythrocyte ω-3
fatty acid α-Linoleic Acid in HD patients compared to
healthy controls. This reduction may be due to the con-
version of ALA into EPA and possibly into DHA. The
conversion of ALA into EPA is limited in humans, but
may be physiologically and clinically important. Several
dietary factors are thought to influence the conversion of
ALA into EPA, the kind of protein consumed and the
amount of dietary EPA among others [20]. Another pos-
sible reason for lower erythrocyte ALA in HD patients is
that many foods rich in ALA (such as nuts, seeds and seed
oils including flaxseed oil, English walnuts, canola oil, and
soybean oil) are not recommended in uremic patients be-
cause they are rich in potassium.Furthermore, HD patients exhibited a significant de-
crease of erythrocyte membrane LA and ARA that re-
duces the cardiovascular protective effect exerted by LA,
as reported by Laaksonen et al. [30]. Arachidonic acid, a
ω-6 fatty acid, is a substrate for the production of vari-
ous pro-oxidant pro-inflammatory mediators and signal
transduction molecules.
In previous investigations a significant increase of
erythrocyte membrane fatty acids were reported in Korean
ESRD patients [31]. The reason for these discrepant data
is unclear. However, differences in dietary composition,
genetic factors [32] and different analytical methods that
have been standardized only recently may be advocated.
We finally observed both plasma and erythrocyte ω6/
ω3 ratios increased in HD patients compared to healthy
controls; in earlier prospective studies the supplementa-
tion of ω3 fatty acid reduced membrane ω6/ω3 ratio sig-
nificantly in these patients and lowered plasma ARA in
healthy subjects and in patients with coronary heart dis-
ease [33,34]. The CV protective effect of ω-3 PUFAs
may be related to their anti-thrombotic, lipid-lowering
and anti-inflammatory actions [35,36].
Limitations
The main limitation of our study was a correct evaluation
of the real feeding habits of HD patients on “free” diet by
means of a self-administered questionnaire. A significant
discrepancy is patent when the mean caloric intake re-
ported by patients is compared to their “real” caloric in-
take derived from BMI calculation (see Table 3, lines 1 to
3). This underestimation of the reported caloric intake
may be due to a low adherence of patients to dietary pre-
scriptions and subsequent insincere answers.
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Ω-3 PUFAs may reduce this risk in the general popula-
tion. A dietary treatment addressed to increase plasma
ω-3 PUFAs EPA and DHA and to optimize ω-6/ω-3 ratio
may exert a protective action and reduce the risk of CVD
also in HD patients. The fatty acid composition of erythro-
cyte cell membrane reflects that of the myocardiocyte and
is influenced by diet. Our study suggests that the analysis
of PUFAs in plasma and erythrocyte membranes could
help to identify subjects who might take advantage from a
change in the dietary intake addressed to optimize the ω-
6/ω-3 ratio.
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